Molecular Partners AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Patrick Amstutz
- Full Time Employees
- 158
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Wagistrasse 14 Schlieren Switzerland 8952
- IPO Date
- Jun 14, 2018
- Website
- molecularpartners.com
- Similar Companies
- Business
- Molecular Partners AG Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design, development, and commercialization of DARPin therapeutics, a proprietary class of custom-built, small-protein drugs offering multi-specificity, high potency, and versatility for challenging medical indications including oncology, immuno-oncology, ophthalmology, infectious diseases, and hematology. The company offers an advancing pipeline of DARPin-based candidates such as MP0712, a 212Pb-labeled Radio-DARPin targeting DLL3 for small cell lung cancer and neuroendocrine tumors; MP0726, a 212Pb-labeled Radio-DARPin targeting mesothelin for ovarian cancer; MP0533, a tetra-specific T-cell engager targeting CD33, CD123, CD70, and CD3 for relapsed/refractory acute myeloid leukemia; MP0317, a FAP x CD40 agonist for advanced solid tumors; MP0621, a cKIT x CD16a x CD47 Switch-DARPin for hematopoietic stem cell conditioning; and ensovibep, a tri-specific antiviral for SARS-CoV-2. Molecular Partners operates primarily in Switzerland and the United States, with approximately 150 employees focused on proprietary programs and collaborations with pharmaceutical leaders; founded in 2004, the company maintains headquarters in Schlieren-Zürich, Switzerland, and offices in Concord and Cambridge, Massachusetts, USA. Recent developments include the expansion in January 2025 of its strategic co-development partnership with Orano Med to encompass ten 212Pb-based Radio-DARPin programs, building on the initial January 2024 agreement covering four programs with Molecular Partners retaining commercialization rights for leads like MP0712 and MP0726; a $20 million underwritten equity offering in October 2024 to fund radiopharmaceutical pipeline expansion; advancement of MP0712 toward a first-in-human study in 2025 pending regulatory clearance; presentation of new preclinical data on logic-gated CD3 Switch-DARPins and MP0712 imaging at scientific congresses in late 2025; and reporting CHF 149 million in cash equivalents as of December 31, 2024.
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript
Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript
Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript
Molecular Partners AG (MOLN) Q4 2022 Earnings Call Transcript
Molecular Partners AG (MOLN) Q2 2022 Earnings Call Transcript
Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant
Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States
Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19
Molecular Partners to Present Data from Localized Immune Agonist (MP0317), T-cell Engager, and Peptide-MHC Immunotherapy Programs at AACR Annual Meeting